



PEER-REVIEWED PUBLICATIONS

Academic year 2024: July 1, 2023 – June 20, 2024

1. Ajithkumar T, Avanzo M, Yorke E, Tsang DS, Milano MT, Olch AJ, Merchant TE, Dieckmann K, Mahajan A, Fuji H, Paulino AC, Timmermann B, Marks LB, **Bentzen SM**, Jackson A, Constine LS. PENTEC organ-specific report: Brain and brain stem necrosis after reirradiation for recurrent childhood primary central nervous system tumors: A PENTEC comprehensive review. *Int J Radiat Oncol Biol Phys*. 2024 Feb 1:S0360-3016(24)00001-4. Online ahead of print.
2. **Alexander GS, Krc RF, Assif JW, Sun K, Molitoris JK, Tran P, Rana Z, Bentzen SM, Mishra MV**. Conditional risks of biochemical failure and prostate cancer-specific death in patients undergoing external beam radiotherapy: A secondary analysis of 2 randomized clinical trials. *JAMA Netw Open*. 2023 Sep 5;6(9):e2335069.
3. **Alexander GS, Krc RF, Assif JW, Sun K, Molitoris JK, Tran P, Rana Z, Mishra MV**. Conditional risk and predictive factors associated with late toxicity for prostate cancer patients treated with external beam radiotherapy alone on randomized trial RTOG 0126. *Int J Radiat Oncol Biol Phys*. 2024 May 31:S0360-3016(24)00686-2. Ahead of print.
4. **Alexander GS, Pollock AE**, Arons D, **Ferris MJ, Molitoris JK, Regine WF**, Witek ME. Post-treatment PET/CT for p16-positive oropharynx cancer treated with definitive proton therapy. *J Clin Imaging Sci*. 2023 Sep 29;13:31.
5. Atanackovic D, Iraguha T, Omili D, Avila SV, Fan X, Kocoglu M, Gebru E, Baker JM, Dishanthan N, Dietze KA, Olwafemi A, Hardy NM, Yared JA, **Hankey K**, Dahiya S, Rapoport AP, Luetkens T. A novel multicolor fluorescent spot assay for the functional assessment of chimeric antigen receptor (CAR) T-cell products. *Cytotherapy*. 2024 Apr; 26(4):318-324.
6. Batchelor TT, Won M, Chakravarti A, Hadjipanayis CG, Shi W, Ashby LS, Stieber VW, Robins HI, Gray HJ, Voloschin A, Fiveash JB, Robinson CG, Chamarthy U, **Kwok Y**, Cescon TP, Sharma AK, Chaudhary R, Polley MY, Mehta MP. NRG/RTOG 0837: Randomized, phase II, double-blind, placebo-controlled trial of chemoradiation with or without cediranib in newly diagnosed glioblastoma. *Neurooncol Adv*. 2023 Oct 11;5(1):vdad116.
7. **Bazyar S**, Mannuel H, **Tran PT**. Stereotactic ablative radiation therapy in metastatic prostate cancer. *Curr Opin Oncol*. 2024 Feb 15. Online ahead of print.
8. **Bazyar S**, Sutera P, Deek MP, Marshall CH, **Tran PT**. Cell-free DNA sequencing sheds additional insights on BRCA-altered metastatic castration-resistant prostate cancer. *EBioMedicine*. 2023 Aug 9;95:104756. Online ahead of print.
9. **Bentzen SM**, Vogelius IR, Hodgson D, Howell R, Jackson A, Hua CH, Olch AJ, Ronckers C, Kremer L, Milano M, Marks LB, Constine LS. Radiation dose-volume-response relationships for adverse events in childhood cancer survivors: Introduction to the scientific issues in PENTEC. *Int J Radiat Oncol Biol Phys*. 2024 Jun 1;119(2):338–353.
10. **Biswal NC, Zhang B, Nichols E, Witek ME, Regine WF, Yi B**. Cone-beam CT images as an indicator of QACT during adaptive proton therapy of extremity sarcomas. *Int J Part Ther*. 2024 Apr 26;12:100017.
11. **Brown MH**, Macrom SR, Patel MP, Popple RA, Travis RL, McDonald AM, O’Riley KO, Markert JM, Willey CD, Bredel M, Fiveash JB, Thomas EM. Understanding the effect of

- prescription isodose in single-fraction stereotactic radiosurgery on plan quality and clinical outcomes for solid brain metastases. *Neurosurgery*. 2023;93(6):1313–1318.
12. **Byrne KE, Poirier Y, Xu J**, Gerry A, Foley MJ, Jackson IL, **Sawant A, Jiang K**. Technical note: A small animal irradiation platform for investigating the dependence of the FLASH effect on electron beam parameters. *Med Phys*. 2024 Jan 11. Online ahead of print.
 13. **Cammin J**. A robust index for metal artifact quantification in computed tomography. *J Appl Clin Med Phys*. 2024 Jun 25:e14453. Online ahead of print.
 14. **Cao Y, Kunaprayoon D, Ren L**. Interpretable AI-assisted clinical decision making (CDM) for dose prescription in radiosurgery of brain metastases. *Radiother Oncol*. 2023 Aug 3:109842. Online ahead of print.
 15. Casey DL, Vogelius IR, Brodin NP, Roberts KB, Avanzo M, Moni J, Owens C, Ronckers CM, Constine LS, **Bentzen SM**, Olch A. Risk of subsequent neoplasms in childhood cancer survivors after radiation therapy: A comprehensive PENTEC review. *Int J Radiat Oncol Biol Phys*. 2023 Sep 29:S0360-3016(23)07685-X. Online ahead of print.
 16. Chen JJ, Brown AM, Garda AE, Kim E, **McAvoy SA**, Perni S, Rooney MK, Shiue K, Tønning KL, Warren LE, Golden DW, Croke JM; Radiation Oncology Education Collaborative Study Group (ROECSSG) Patient Education Working Group. Patient education practices and preferences of radiation oncologists and interprofessional radiation therapy care teams: A mixed methods study exploring strategies for effective patient education delivery. *Int J Radiat Oncol Biol Phys*. 2024 Mar 2:S0360-3016(24)00332-8.
 17. **Cherng HR**, Qu M, Zafari Z, **Bentzen S**, Armstrong TS, Gondi V, Brown PD, Mehta M, **Mishra MV**. Evaluating the sensitivity of EQ-5D-5L in patients with brain metastases: a secondary analysis of NRG CC001. *J Natl Cancer Inst*. 2024 Jan 27. Online ahead of print.
 18. **Cherng HR, Sun K, Bentzen S**, Armstrong TS, Gondi V, Brown PD, Mehta M, **Mishra MV**. Evaluating the heterogeneity of hippocampal avoidant whole brain radiotherapy treatment effect: A secondary analysis of NRG CC001. *Neuro Oncol*. 2023 Dec 9:noad226. Online ahead of print.
 19. Cheung CK, Jones LP, Lee H, Bridges JN, Tucker-Seeley R, **Vyfhuis MAL**, Gianelle M, Thomas BN, Betz GD, Waldo L, Hirsch A, Ntiri SO. Anticipatory guidance: Developing a patient navigation pathway to reduce the financial toxicity of cancer. *Med Res Arch*. Oct 2023;11(10).
 20. Constine LS, Marks LB, Milano MT, Ronckers CM, Jackson A, Hudson MM, Marcus KJ, Hodgson DC, Hua CH, Howell RM, Marples B, Yorke E, Olch A, **Bentzen SM**. A user's guide and summary of Pediatric Normal Tissue Effects in the Clinic (PENTEC): Radiation dose-volume response for adverse effects after childhood cancer therapy and future directions. *Int J Radiat Oncol Biol Phys*. 2023 Nov 23:S0360-3016(23)07918-X. Online ahead of print.
 21. Constine LS, Olch AJ, Marks LB, Jackson A, **Bentzen SM**. PENTEC dedication and acknowledgments. *Int J Radiat Oncol Biol Phys*. 2024 Jun 1;119(2):315.
 22. Deek MP, Sutera P, Jing Y, Gao R, Rothman E, Day H, Chang D, Dirix P, Armstrong AJ, Campbell B, Campos FL, Berenguer M, Ramotar M, Conde-Moreno A, Berlin A, Bosetti DG, Corcoran N, Koontz B, Mercier C, Siva S, Pryor D, Ost P, Huynh MA, Kroeze S, Stish B, Kiess A, Trock B, **Tran PT**, Gillessen S, Sweeney C. Multi-institutional analysis of metastasis-directed therapy with or without androgen deprivation therapy in oligometastatic castration-sensitive prostate cancer. *Eur Urol Oncol*. 2024 Apr 2:S2588-9311(24)00086-5. Online ahead of print.
 23. Deek MP, **Tran PT**, Jabbour SK. Metastasis-directed therapy: a moving target advancing progress forward. *J Clin Oncol*. 2023 Sep 25:JCO2301274. Online ahead of print.
 24. Elnaggar M, Chaisuparat R, Ghita I, **Bentzen SM**, Dyalram D, Ord RA, Lubek JE, Younis RH. Immuno-oncologic signature of malignant transformation in oral squamous cell carcinoma. *Oral Surg Oral Med Oral Pathol Oral Radiol*. 2023 Nov;136(5):612-622
 25. Hahn EA, Pugh SL, Lu HL, Vela AM, Gillespie EF, **Nichols EM**, Wright JL, MacDonald SM, Cahlon O, Baas C, Braunstein LZ, Fang LC, Freedman GM, Jimenez RB, Kesslering CM, **Mishra MV**, Mutter RW, Ohri N, Rosen LR, Urbanic JJ, Jagsi R, Mitchell SA, Bekelman JE, Cella D; RadComp Consortium. Validation of patient-reported outcomes in

- patients with nonmetastatic breast cancer receiving comprehensive nodal irradiation in the RadComp trial. *Int J Radiat Oncol Biol Phys*. 2024 May 13:S0360-3016(24)00436-X. Ahead of print.
26. Hoang T, Sutera P, **Nguyen T, Chang J, Jagtap S, Song Y, Shetty AC**, Chowdhury DD, Chan A, **Carrieri FA**, Hathout L, Ennis R, Jabbour SK, Parikh R, **Molitoris J**, Song DY, DeWeese T, Marchionni L, **Ren L, Sawant A**, Simone N, **Lafargue A**, Van Der Eecken K, Bunz F, Ost P, **Tran PT**, Deek MP. TP53 structure-function relationships in metastatic castrate-sensitive prostate cancer and the impact of APR-246 treatment. *Prostate*. 2023 Oct 9. Online ahead of print.
 27. Hua CH, **Bentzen SM**, Li Y, Milano MT, Rancati T, Marks LB, Constine LS, Yorke E D, Jackson A. Improving pediatric normal tissue radiation dose-response modeling in children with cancer: A PENTEC initiative. *Int J Radiat Oncol Biol Phys*. 2024 Jan 25:S0360-3016(23)08171-3. Online ahead of print.
 28. Jackson A, Hua CH, Olch A, Yorke ED, Rancati T, Milano MT, Constine LS, Marks LB, **Bentzen SM**. Reporting standards for complication studies of radiation therapy for pediatric cancer: Lessons from PENTEC. *Int J Radiat Oncol Biol Phys*. 2024 Jun 1;119(2):697–707.
 29. Jiang Z, Wang S, Xu Y, Sun L, Gonzalez G, Chen Y, Wu QJ, Xiang L, **Ren L**. Radiation-induced acoustic signal denoising using a supervised deep learning framework for imaging and therapy monitoring. *Phys Med Biol*. 2023 Oct 11. Online ahead of print.
 30. Kathari YK, Ahmad H, Kallen ME, Koka R, Omili D, Iraguha T, Clement J, Pham L, Khalid M, Fan X, Gebru E, Lesho P, Park E, Dishanthan N, Baker JM, Dietze KA, **Hankey KG**, Badros A, Yared JA, Dahiya S, Hardy NM, Kocoglu H, Luetkens T, Rapoport AP, Atanackovic D. Immune-mediated facial nerve paralysis in a myeloma patient post B-cell maturation antigen-targeted chimeric antigen receptor T cells. *Haematologica*. 2023 Sep 7. Online ahead of print.
 31. Kishan AU, Siva S, Hofman MS, Nagarajah J, Kiess AP, **Tran P**, Calais J. The potential contribution of radiopharmaceutical therapies in managing oligometastatic disease. *J Nucl Med*. 2024 Feb 15. Online ahead of print.
 32. Kline K, Luetkens T, Koka R, Kallen Me, Chen W, Ahmad H, Omili D, Iraguha T, Gebru E, Fan X, Miller A, Dishanthan N, Baker JM, Dietze KA, **Hankey KG**, Yared JA, Hardy NM, Rapoport AP, Dahiya S, Atanackovic D. Treatment of secondary CNS lymphoma using CD19-targeted chimeric antigen receptor (CAR) T cells. *Cancer Immunol Immunother*. 2024 Feb 13;73(3):45.
 33. **Krc R, Mendes W, Molitoris J, Ferris M, Song Y, Shetty A**, Mehra R, Papadimitriou JC, Hatten K, Taylor R, Wolf J, **Sun K, Bentzen S, Regine W, Tran P**, Witek M. Proton therapy re-irradiation outcomes and genomic landscape of patients with recurrent head and neck cancer. *Oral Oncol*. 2024 Jun 1;154:106875. Ahead of print.
 34. Lang Y, Jiang Z, Sun L, Xiang L, **Ren L**. Hybrid-supervised deep learning for domain transfer 3D protoacoustic image reconstruction. *Phys Med Biol*. 2024 Apr 3;69(8).
 35. Langevin B, Singh P, Plett PA, Sampson CH, Masters A, **Gibbs A, Faria E, Triesler S, Zodda A**, Jackson IL, Orschell CM, Gopalakrishnan M, Pelus LM. Pharmacokinetics and biodistribution of 16,16 dimethyl prostaglandin E2 in non-irradiated and irradiated mice and non-irradiated non-human primates. *Radiat Res*. 2023 Nov 29. Online ahead of print.
 36. Li H, Mayr NA, Griffin RJ, Zhang H, Pokhrel D, Grams M, Penagaricano J, Chang S, Spraker MB, Kavanaugh J, Lin L, Sheikh K, **Mossahebi S**, Simone CB 2nd, Roberge D, Snider JW, Sabouri P, Molineu A, Xiao Y, Benedict SH. Overview and recommendations for prospective multi-institutional clinical trials of spatially fractionated radiation therapy (SFRT). *Int J Radiat Oncol Biol Phys*. 2023 Dec 16:S0360-3016(23)08246-9. Online ahead of print.
 37. Li R, Zhuang T, Montalvo S, **Wang K**, Parsons D, Zhang Y, Iyengar P, Wang J, Godley A, Cai B, Lin MH, Westover K. Adapt-on-demand: A novel strategy for personalized adaptive radiotherapy for locally advanced lung cancer. *Pract Radiat Oncol*. 2024 Apr 3:S1879-8500(24)00078-X. Online ahead of print.

38. **Ling X**, Alexander GS, **Molitoris J**, Choi J, Schumaker L, Mehra R, Gaykalova DA, **Ren L**. Identification of CT-based non-invasive radiomic biomarkers for overall survival prediction in oral cavity squamous cell carcinoma. *Sci Rep*. 2023 Dec 8;13(1):21774.
39. Ling X, Alexander GS, **Molitoris J**, Choi J, Schumaker L, **Tran P**, Mehra R, Gaykalova D, **Ren L**. Radiomic biomarkers of locoregional recurrence: prognostic insights from oral cavity squamous cell carcinoma preoperative CT scans. **Front Oncol**. 2024 Apr 23;14:1380599.
40. Mak KS, Scannell Bryan M, Dignam JJ, Shipley WU, Lin Y, Peters CA, Gore EM, Rosenthal SA, Zeitzer KL, D'Souza DP, Horwitz EM, Pisansky TM, Maier JM, Chafe SM, Robin TP, Roach M 3rd, **Tran PT**, Souhami L, Michalski JM, Hartford AC, Feng FY, Sandler HM, Efstathiou JA. Cardiovascular mortality and duration of androgen deprivation in locally advanced prostate cancer: Long-term update of NRG/RTOG 9202. *Eur Urol Focus*. 2024 Feb 1:S2405-4569(24)00011-7. Online ahead of print.
41. Markan U, **Baker K**, **Eggleston C**, **Cheston SB**, Mohindra P, **Nichols E**, **McAvoy S**, **Bentzen SM**, **Vyfhuis MAL**. Psychosocial factors that influence a woman's decision to enroll in a clinical trial - implications on how to improve clinical trial enrollment among Black women. *Int J Radiat Oncol Biol Phys*. 2024 Feb 20:S0360-3016(24)00328-6. Online ahead of print.
42. Mayr NA, Mohiuddin M, Snider JW, Zhang H, Griffin RJ, Amendola BE, Hippe DS, Perez NC, Wu X, Lo SS, **Regine WF**, Simone CB 2nd. Practice patterns of spatially fractionated radiation therapy: A clinical practice survey. *Adv Radiat Oncol*. 2024 Feb eCollection.
43. Meiller TF, Fraser CM, Grant-Beurmann S, Humphrys M, Tallon L, Sadzewicz LD, Jabra-Rizk MA, Alfaifi A, Kensara A, **Molitoris JK**, Witek M, Mendes WS, **Regine WF**, **Tran PT**, Miller RC, Sultan AS. A longitudinal metagenomic comparative analysis of oral microbiome shifts in patients receiving proton radiation versus photon radiation for head and neck cancer. *J Cancer Allied Spec*. 2024 Jan 22;10(1):579.
44. Mell LK, Pugh SL, Jones CU, Nelson TJ, Zakeri K, Rose BS, Zeitzer KL, Gore EM, Bahary JP, Souhami L, Michalski JM, Hartford AC, **Mishra MV**, Roach M 3rd, Parliament MB, Choi KN, Pisansky TM, Husain SM, Malone SC, Horwitz EM, Feng F. Effects of androgen deprivation therapy on prostate cancer outcomes according to competing event risk: Secondary analysis of a phase 3 randomised trial. *Eur Urol*. 2024 Apr;85(4):373-381.
45. Milano MT, Marks LB, Olch AJ, Yorke ED, Jackson A, **Bentzen SM**, Constone LS. Comparison of risks of late effects from radiation therapy in children versus adults: Insights from the QUANTEC, HyTEC, and PENTEC efforts. *Int J Radiat Oncol Biol Phys*. 2023 Dec 7:S0360-3016(23)07910-5. Online ahead of print. Review.
46. Morgan TM, Boorjian SA, Buyyounouski MK, Chapin BF, Chen DYT, Cheng HH, Chou R, Jacene HA, Kamran SC, Kim SK, Kirkby E, Luckenbaugh AN, Nathanson BJ, Nyame YA, Posadas EM, **Tran PT**, Chen RC. Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part I: Introduction and treatment decision-making at the time of suspected biochemical recurrence after radical prostatectomy. *J Urol*. 2024 Feb 14. Online ahead of print.
47. Morgan TM, Boorjian SA, Buyyounouski MK, Chapin BF, Chen DYT, Cheng HH, Chou R, Jacene HA, Kamran SC, Kim SK, Kirkby E, Luckenbaugh AN, Nathanson BJ, Nyame YA, Posadas EM, **Tran PT**, Chen RC. Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part III: Salvage therapy after radiotherapy or focal therapy, pelvic nodal recurrence and oligometastasis, and future directions. *J Urol*. 2024 Feb 14. Online ahead of print.
48. Morgan TM, Boorjian SA, Buyyounouski MK, Chapin BF, Chen DYT, Cheng HH, Chou R, Jacene HA, Kamran SC, Kim SK, Kirkby E, Luckenbaugh AN, Nathanson BJ, Nyame YA, Posadas EM, **Tran PT**, Chen RC. Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part II: Treatment delivery for non-metastatic biochemical recurrence after primary radical prostatectomy. *J Urol*. 2024 Feb 14. Online ahead of print.
49. **Mossahebi S**, **Molitoris JK**, **Poirier Y**, **Jatczak J**, **Zhang B**, **Mohindra P**, **Ferris M**, **Regine WF**, **Yi B**. Clinical implementation and dosimetric evaluation of a robust proton

- lattice planning strategy using primary and robust complementary beams. *Int J Radiat Oncol Biol Phys*. 2024 Jun 25:S0360-3016(24)00742-9. Online ahead of print.
50. Mumaw DA, Hazy AJ, Vayntraub A, Quinn TJ, Salari K, Chang JH, Kalman N, Katz S, Urbanic J, Press RH, Thukral AD, Tsai H, Laramore GE, **Molitoris J**, Vargas C, Patel SH, Stevens C, Deraniyagala. Low contralateral failure rate with unilateral proton beam radiotherapy for oropharyngeal squamous cell carcinoma: A multi-institutional prospective study from the Proton Collaborative Group. *Radiother Oncol*. 2024 Jan;190:109977.
 51. **Nichols EM**, Bentzen SM, Millburn M, Kesmodel SB, Bellavance E, **Becker SJ**, Mutaf Y, Tkaczuk K, Rosenblatt P, Feigenberg SJ. A prospective trial of single-fraction radiation to the tumor bed with a novel breast-specific stereotactic radiation therapy device: The GammaPod. *Adv Radiat Oncol*. 2024;9(4):101398.
 52. **Nguyen T**, **Carrieri FA**, Connis N, **Lafargue A**, Chang J, Chan A, Shetty AC, Song Y, Hoang T, Jagtap S, Chowdhury DD, Khan MA, Gabrielson KL, Rezaee M, Torres-Ayuso P, Brognard J, Hann CL, **Tran PT**. TNIK inhibition sensitizes TNIK-overexpressing lung squamous cell carcinoma to radiotherapy. *Mol Cancer Ther*. 2024 Apr 27. Online ahead of print.
 53. Okunieff P, Swarts SG, Fenton B, Zhang SB, Zhang Z, Rice L, Zhou D, **Carrier F**, Zhang L. Radiation biological toximetry using circulating cell-free DNA (cfDNA) for rapid radiation/nuclear triage. *Radiat Res*. 2024 Apr 25. Online ahead of print.
 54. Orekoya AA, Abdus-Salam AA, Oysegun AR, Ntekim AI, Folasire AM, Okolo CA, **Olabumuyi AA**, Dada AA, Adenipekun AA. EGFR and HER2 expression in cervical cancer patients in Ibadan, Nigeria. *Ecancermedicalscience*. 2023;17:1607.
 55. Onal C, Guler OC, Erpolat P, Hurmuz P, Sutera P, Deek MP, Elmali A, Yilmaz MT, Koken UH, Yavuz M, Ozyigit G, **Tran PT**. Evaluation of treatment outcomes of prostate cancer patients with lymph node metastasis treated with definitive radiotherapy: Comparative analysis of PSMA PET/CT and conventional imaging. *Clin Nucl Med*. 2024 Jun 3. Ahead of print.
 56. **Poirier Y**, DeWerd LA, Trompier F, Santos MD, Sheng K, Kunugi K, Satyamitra MM, DiCarlo AL, Winters TA. Minimum reporting standards should be expected for preclinical radiobiology irradiators and dosimetry in the published literature. *Radiat Res*. 2023 Aug 8. Online ahead of print.
 57. Pollock AE, Risher H, Berger M, Roque DM, Rao G, **Nichols EM**, Mohindra P. Clinical outcomes of intensity modulated proton therapy reirradiation for gynecologic malignancies. *Adv Radiat Oncol*. eCollection 2023 Jul-Aug.
 58. Prabhu RS, Akinyelu T, Vaslow ZK, Matsui JK, Haghghi N, Dan T, **Mishra MV**, Murphy ES, Boyles S, Perlow HK, Palmer JD, Udovicich C, Patel TR, Wardak Z, Woodworth GF, Ksendzovsky A, Yang K, Chao ST, Asher AL, Burri SH. Single fraction vs. fractionated preoperative radiosurgery for resected brain metastases: A PROPS-BM international multicenter cohort study. *Int J Radiat Oncol Biol Phys*. 2023 Sep 15:S0360-3016(23)07924-5. Online ahead of print.
 59. Prabhu RS, Akinyelu T, Vaslow ZK, Matsui JK, Haghghi N, Dan T, **Mishra MV**, Murphy ES, Boyles S, Perlow HK, Palmer JD, Udovicich C, Patel TR, Wardak Z, Woodworth GF, Ksendzovsky A, Yang K, Chao ST, Asher AL, Burri SH. Risk factors for progression and toxic effects after preoperative stereotactic radiosurgery for patients with resected brain metastases. *JAMA Oncol*. 2023;9(8):1066–1073.
 60. **Rahimi R**, Emert F; PTCOG Treatment Efficiency Subcommittee. Introducing the good clinical proton practice (GCPP) initiative for enhancing proton therapy standards. *J Appl Clin Med Phys*. 2024 Jun 18:e14436. Online ahead of print.
 61. **Rahimi R**, Taylor M, Li X, Chen KL, MacLennan G, Murdoch E, Chang L, Parniani A, Wang P, Chawla A, Fan J, Kim D. Fetal dose assessment in a pregnant patient with brain tumor: A comparative study of proton PBS and 3DCRT/VMAT radiation therapy techniques. *J Appl Clin Med Phys*. 2024 Jun 17:e14394. Online ahead of print.
 62. **Rana Z**, Kamran SC, Shetty AC, Sutera P, Song Y, **Bazyar S**, Solanki AA, Simko JP, Pollack A, McConkey D, Kates M, Siddiqui MM, Hiken J, Earls J, Messina D, Mouw KW, Miyamoto D, Shipley WU, Michaelson MD, Zietman A, Coen JJ, Dahl DM, Jani AB,

- Souhami L, Chang BK, Lee RJ, Pham H, Marshall DT, Shen X, Pugh SL, Feng FY, Efstathiou JA, **Tran PT**, Deek MP. Prognostic significance of immune cell infiltration in muscle-invasive bladder cancer treated with definitive chemoradiation: A secondary analysis of RTOG 0524 and RTOG 0712. *Eur Urol Oncol*. 2024 Apr 18:S2588-9311(24)00095-6. Online ahead of print.
63. Ross AE, Zhang J, Huang HC, Yamashita R, Keim-Malpass J, Simko JP, DeVries S, Morgan TM, Souhami L, Dobelbower MC, McGinnis LS, Jones CU, Dess RT, Zeitzer KL, Choi K, Hartford AC, Michalski JM, Raben A, Gomella LG, Sartor AO, Rosenthal SA, Sandler HM, Spratt DE, Pugh SL, Mohamad O, Esteva A, Chen E, Schaeffer EM, **Tran PT**, Feng FY. External validation of a digital pathology-based multimodal artificial intelligence architecture in the NRG/RTOG 9902 phase 3 trial. *Eur Urol Oncol*. 2024 Jan 31. Online ahead of print.
64. **Roy S, Dukic T**, Keepers Z, **Bhandary B, Lamichhane N, Molitoris J**, Ko YH, **Banerjee A, Shukla HD**. SOX2 and OCT4 mediate radiation and drug resistance in pancreatic tumor organoids. *Cell Death Discov*. 2024 Mar 1;10(1):106.
65. Sabouri P, **Molitoris J**, Ranjbar M, Moreau J, Simone CB 2nd, Mohindra P, Langen K, **Mossahebi S**. Dosimetric evaluation and reproducibility of breath-hold plans in intensity modulated proton therapy: An initial clinical experience. *Adv Radiat Oncol*. 2023 Oct 21;9(3):101392. eCollection 2024 Mar.
66. Saeed AM, **Bentzen SM**, Ahmad H, Pham L, Woodworth GF, **Mishra MV**. Correction: Systematic review and pooled analysis of the impact of treatment-induced lymphopenia on survival of glioblastoma patients. *Radiat Oncol*. 2024 May 15;19(1):58.
67. Saeed AM, **Bentzen SM**, Ahmad H, Pham L, Woodworth GF, **Mishra MV**. Systematic review and pooled analysis of the impact of treatment-induced lymphopenia on survival of glioblastoma patients. *Radiat Oncol*. 2024 Mar 14;19(1):36.
68. Saha M, Jung JW, **Lee SW**, Lee C, Lee C, Mille MM. A deep learning segmentation method to assess dose to organs at risk during breast radiotherapy. *Phys Imaging Radiat Oncol*. 2023 Nov 21;28:100520.
69. Shaitelman SF, Anderson BM, Arthur DW, Bazan JG, Bellon JR, Bradfield L, Coles CE, Gerber NK, Kathpal M, Kim L, Laronga C, Meattini I, **Nichols EM**, Pierce LJ, Poppe MM, Spears PA, Vinayak S, Whelan T, Lyons JA. Partial breast irradiation for patients with early-stage invasive breast cancer or ductal carcinoma in situ: An ASTRO clinical practice guideline. *Pract Radiat Oncol*. 2023 Nov 14:S1879-8500(23)00296-5. Online ahead of print.
70. Sheikh E, Agrawal K, **Roy S**, Burk D, Donnarumma F, Ko YH, Guttula PK, **Biswal NC, Shukla HD**, Gartia MR. Multimodal imaging of pancreatic cancer microenvironment in response to an antiglycolytic drug. *Adv Healthc Mater*. 2023 Sep 14:e2301815. Online ahead of print.
71. So EC, Zhou H, Greenwell A, Burch EE, Ji Y, Mérigeon EY, Olsen HS, **Bentzen SM**, Block DS, Zhang X, Strome SE. Complement component C1q is an immunological rheostat that regulates Fc:Fc[Formula: see text]R interactions. *Immunogenetics*. 2023 Aug;75(4):369–383.
72. Sokolov D, Sharda N, Banerjee A, Denisenko K, Basalious EB, **Shukla H**, Waddell J, Hamdy NM, Banerjee A. Differential signaling pathways in medulloblastoma: Nano-biomedicine targeting non-coding epigenetics to improve current and future therapeutics. *Curr Pharm Des*. 2023 Dec 27. Online ahead of print.
73. Spruijt K, **Mossahebi S**, Lin H, Lee E, Kraus J, Dhabaan A, Poulsen P, Lowe M, Ayan A, Spiessens S, Godart J, Hoogeman M. Multi-institutional consensus on machine QA for isochronous cyclotron-based systems delivering ultra-high dose rate (FLASH) pencil beam scanning proton therapy in transmission mode. *Med Phys*. 2023 Dec 16. Online ahead of print.
74. Stern W, Alaei P, Berbeco R, DeWerd LA, Kamen J, MacKenzie C, Moros EG, **Poirier Y**, Potter CA, Schae D, Patallo IS, Abend M, Swarts S, Tromprier F. Achieving consistent reporting of radiation dosimetry by adoption of Compatibility in Irradiation Research

- Protocols Expert Roundtable (CIRPER) recommendations. *Radiat Res.* 2024 Jan 11. Online ahead of print.
75. Stern W, Parham A, Berbeco R, DeWerd LA, Kamen J, MacKenzie C, Moros EG, **Poirier Y**, Potter CA, Schae D, Patallo IS, Abend M, Swarts S, Trompier F. Recommendations for harmonized reporting of radiation dosimetry by adoption of Compatibility in Irradiation Research Protocols Expert Roundtable (CIRPER). *Int J Radiat Biol.* 2024 Apr 3:1-3. Online ahead of print.
 76. Stokkevåg CH, Journy N, Vogelius IR, Howell RM, Hodgson D, **Bentzen SM**. Radiation therapy technology advances and mitigation of subsequent neoplasms in childhood cancer survivors. *Int J Radiat Oncol Biol Phys.* 2024 Mar 1:S0360-3016(24)00250-5. Online ahead of print.
 77. Studenski MT, Cetnar A, Derosiers CM, Dooley S, Gagneur JD, Galavis PE, Kainz KK, Lamichhane, Sandwall PA, Shen J, Tien CJ, Wang D, Wang IZ, Warkentin HK, McAvoy S. The AAPM/ASTRO 2023 core physics curriculum for radiation oncology residents. *Int J Radiat Oncol Biol Phys.* 2024;118(2):325–329.
 78. Sutera P, Deek MP, Deek RA, Guler OC, Hurmuz P, Reyhan M, Rowe S, Radwan N, Dipasquale S, Hrinivich WT, Lowe K, **Ren L**, Saraiya B, Ennis R, Hathout L, Mayer T, Deweese TL, Song DY, Kiess A, Oymak E, Pienta K, Feng F, Pomper M, Ozyigit G, **Tran PT**, Onal C, Phillips RM. Prostate-specific membrane antigen PET response associates with metastasis-free survival after stereotactic ablative radiation in oligometastatic prostate cancer. *Adv Radiat Oncol.* 2024 Apr 13;9(7):101507.
 79. Sutera P, Shetty AC, Song Y, Hodges T, Hoang T, **Rana Z**, Pienta K, Feng F, Song DY, DeWeese T, Gillissen S, Sweeney C, James N, Attard G, Deek M, **Tran PT**. Identification of a predictive genomic biomarker for prostate-directed therapy in synchronous low-volume metastatic castration-sensitive prostate cancer. *Eur Urol Oncol.* 2023 Aug 8:S2588-9311(23)00156-6. Online ahead of print.
 80. Sutera P, Skinner H, Witek M, **Mishra M**, **Kwok Y**, Davicioni E, Feng F, Song D, **Nichols E**, **Tran PT**, Bergom C. Histology specific molecular biomarkers: Ushering in a new era of precision radiation oncology. *Semin Radiat Oncol.* 2023;33(3):232-242.
 81. Sutera P, Song Y, Shetty AC, English K, Van der Eecken K, Guler OC, Wang J, **Cao Y**, Bazyar S, Verbeke S, Van Dorpe J, Fonteyne V, De Laere B, **Mishra M**, **Rana Z**, **Molitoris J**, **Ferris M**, Kiess A, Song DY, DeWeese T, Pienta KJ, Barbieri C, Marchionni L, **Ren L**, **Sawant A**, Simone N, Berlin A, Onal C, **Tran PT**, Ost P, Deek MP. Genomic determinants associated with modes of progression and patterns of failure in metachronous oligometastatic castration-sensitive prostate cancer. *Eur Urol Oncol.* 2024 Jun 10:S2588-9311(24)00142-1.
 82. Taylor SI, **Cherng HR**, Shahidzadeh Yazdi Z, Montasser ME, Whitlatch HB, Mitchell BD, Shuldiner AR, Streeten EA, Beitelshees AL. Pharmacogenetics of sodium-glucose co-transporter-2 inhibitors: Validation of a sex-agnostic pharmacodynamic biomarker. *Diabetes Obes Metab.* 2023 Aug 22. Online ahead of print.
 83. Tchelebi LT, Winter KA, Abrams RA, Safran HP, **Regine WF**, McNulty S, Wu A, Du KL, Seaward SA, Bian SX, Aljumaily R, Shivnani A, Moore TD, Crocenzi TS, DiPetrillo TA, Kuykendal AR, Crane CH, Goodman KA. Analysis of radiation therapy quality assurance in NRG Oncology RTOG 0848. *Int J Radiat Oncol Biol Phys.* 2023 Aug 18:S0360-3016(23)07781-7. Online ahead of print.
 84. Theofilou VI, Ghita I, Elnaggar M, Chaisuparat R, Papadimitriou JC, **Bentzen SM**, Dyalram D, Lubek JE, Ord RA, Younis RH. Histological pattern of tumor inflammation and stromal density correlate with patient demographics and immuno-oncologic transcriptional profile in oral squamous cell carcinoma. *Front Oral Health.* 2024 Jun 6;5:1408072.
 85. **Tran PT**, Mouw KW. SABR today...and tomorrow? *Int J Radiat Oncol Biol Phys.* 2024;118(1):11. Online ahead of print.
 86. Trompier F, DeWerd LA, **Poirier Y**, Dos Santos M, Sheng K, Kunugi KA, Winters TA, DiCarlo AL, Satyamitra M. Commentary: minimum reporting standards should be

- expected for preclinical radiobiology irradiators and dosimetry in the published literature. *Int J Radiat Biol.* 2023 Sep 11:1-6. Online ahead of print.
87. Tu KJ, **Roy SK**, Keepers Z, Gartia MR, **Shukla HD**, **Biswal NC**. Docetaxel radiosensitizes castration resistant prostate cancer by downregulating CAV-1. *Int J Radiat Biol.* 2023 Sep 25:1-13. Online ahead of print.
 88. Valenzi E, Bahudhanapati H, Tan J, Tabib T, Sullivan DI, Nouraie M, Sembrat J, Fan L, Chen K, Liu S, Rojas M, **Lafargue A**, Felsher DW, Tran PT, Kass DJ, Lafyatis R. Single-nucleus chromatin accessibility identifies a critical role for TWIST1 in idiopathic pulmonary fibrosis myofibroblast activity. *Eur Respir J.* 2023 Jul 7;62(1):2200474.
 89. Vasantachart A, **Cao Y**, Shen Z, Cheng K, Gribble M, Ye JC, Zada G, Hurth K, Mathew A, Guzman S, Yang W. A repository of grade 1 and 2 meningioma MRIs in a public dataset for radiomics reproducibility tests. *Med Phys.* 2024 Mar;51(3):2334-2344.
 90. **Vicente EM**, Grande Gutierrez N, Oakes JM, **Cammin J**, **Gopal A**, Kipritidis J, **Modiri A**, **Mossahebi S**, Mohindra P, **Citron WK**, Matuszak MM, Timmerman R, **Sawant A**. Integrating local and distant radiation-induced lung injury: Development and validation of a predictive model for ventilation loss. *Med Phys.* 2024 May 31. Ahead of print.
 91. Voong KR, Illei PB, Presson B, Singh D, Zeng Z, Lanis M, Hales RK, Hu C, **Tran PT**, Georgiades C, Lin CT, Thiboutout J, Brahmer JR, Forde PM, Naidoo J, Anagnostou V, Smith KN. Ablative radiation alone in stage I lung cancer produces an adaptive systemic immune response: insights from a prospective study. *J Immunother Cancer.* 2023 Oct;11(10):e007188.
 92. Wan S, **Rodrigues DB**, Kwiatkowski J, Khanna O, Judy KD, Goldstein RC, Overbeek Bloem M, Yu Y, Rooks SE, Shi W, Hurwitz MD, Stauffer PR. Evaluation of a balloon implant for simultaneous magnetic nanoparticle hyperthermia and high-dose-rate brachytherapy of brain tumor resection cavities. *Cancers (Basel).* 2023 Dec 1;15(23):5683.
 93. Wefel JS, Deshmukh S, Brown PD, Grosshans DR, Sulman EP, Cerhan JH, Mehta MP, Khuntia D, Shi W, **Mishra MV**, Suh JH, Laack NN, Chen Y, Curtis AA, Laba JM, Elsayed A, Thakrar A, Pugh SL, Bruner DW. Impact of apolipoprotein E (APOE) genotype on neurocognitive function (NCF) in patients with brain metastasis (BM): An analysis of NRG Oncology's RTOG 0614. *Int J Radiat Oncol Biol Phys.* 2023 Dec 13:S0360-3016(23)08238-X. Online ahead of print.
 94. Yang AH, Urrunaga NH, Siddiqui O, Wu A, Schliep M, **Mossahebi S**, Shetty K, **Regine WF**, **Molitoris JK**, Lominadze Z. Proton beam stereotactic body radiotherapy and hypofractionated therapy with pencil beam scanning is safe and effective for advanced hepatocellular carcinoma and intrahepatic cholangiocarcinoma: A single center experience. *J Radiosurg SBRT.* 2023;9(1):43-52.
 95. **Yao W**, Farr JB, **Mossahebi S**, **Yi B**, **Chen S**. Technical note: Determination of proton linear energy transfer from the integral depth dose. *Med Phys.* 2023 Dec 3. Online ahead of print.
 96. **Yi B**, **Jaczak J**, **Deng W**, **Poirier YP**, **Yao W**, **Witek ME**, **Molitoris JK**, **Zakhary MJ**, **Zhang B**, **Biswal NC**, **Ferris MJ**, **Mossahebi S**. Is noncoplanar plan more robust to inter-fractional variations than coplanar plan in treating bilateral HN tumors with pencil-beam scanning proton beams? *J Appl Clin Med Phys.* 2023 Nov 16:e14186. Online ahead of print.
 97. **Yi B**, **Mossahebi S**, **Jaczak J**, **Mundis M**, **Houser T**, **Alicia D**, **Han D**, **Gonzalez R**, **Olis S**, **Zakhary M**. Optimal minimum MU for intensity-modulated proton therapy with pencil-beam scanning proton beams. *J Appl Clin Med Phys.* 2024 Jun 23:e14435. Online ahead of print.
 98. **Zarinshenas R**, Campbell P, **Sun K**, **Molitoris JK**, Patel AN, Witek ME, Cullen KJ, Mehra R, Hatten KM, Moyer KF, Taylor RJ, Vakharia KT, Wolf JS, **Ferris MJ**. Disease and toxicity outcomes for a modern cohort of patients with squamous cell carcinoma of cutaneous origin involving the parotid gland: Comparison of volumetric modulated arc therapy and pencil beam scanning proton therapy. *Radiother Oncol.* 2024 Feb 1:110112. Online ahead of print.

99. Zhang H, **Zhang B**, Lasio G, Chen S, Nasehi Tehrani J. Assessing quality assurance of multi-leaf collimator using the structural similarity index. *J Appl Clin Med Phys*. 2024 Feb 12. Online ahead of print.
100. Zhang Y, Jiang Z, Zhang Y, **Ren L**. A review on 4D cone-beam CT (4D-CBCT) in radiation therapy: Technical advances and clinical applications. *Med Phys*. 2024 Jun 23. Online ahead of print.